Staphylococcal toxic shock syndrome toxin 1 (TSST-1) binds to major histocompatibility complex class II molecules, and the toxin-class II complexes induce proliferation of T ceils expressing VB2 sequences. To define the residues involved in TSST-1 binding, a set of transfectants expressing 21 HLA-DRot chain mutants were analyzed for their abilities to bind and present TSST-1 and to present an antigenic peptide. Mutations at DRc~ positions 36 and 39 markedly decreased the ability of the DR7 molecule to bind and present TSST-1 but did not affect the ability to present an antigenic peptide. These data indicate that DRot residues 36 and 39, predicted to be located on an outer loop, are important in the formation of the TSST-1 binding site on DR molecules.
B
acterial superantigens bind to MHC class II molecules and are recognized by specific TCRs inducing potent activation of T cells (1) (2) (3) . They include Staphylococcus aureus enterotoxins (SE)A, SEB, SEC-1, -2, and -3, SED, and SEE, and the exotoxin toxic shock syndrome toxin (TSST-1). TSST-1, the focus of this report, is produced by most strains of S. aureus that cause toxic shock syndrome and appears to be important in the pathophysiology of this disorder (see reference 4 for review and references). In humans, TSST-1 binds well to HLA-DR, interacting with a not-yet-defined region of the DRod domain (5), but poorly or not at all to DP molecules (5-7), and it is specifically recognized by TCRs expressing V32 sequences. However, despite the remarkable degree of structural, regulatory, and functional conservation between DRot and I-Eol chains (8) , TSST-1 does not bind or binds only at a very low degree to routine I-E molecules (7, 9) . Based on previous studies, the view has emerged that bacterial superantigens interact with class II molecules differently than antigenic peptides, perhaps by interactions with the outer surface of these molecules (5, 10, 11) .
The purpose of this study was to define specific residues in the DRc~ chain that are involved in binding and presentation of TSST-1 as compared with presentation of an antigenic peptide. Residues from I-E, DP, or DQot chains were substituted into several analogous positions in the DRot chain, and mutant DRot chains were expressed in transfectants with the wild-type DR(/31"0701) chain. The abilities of these mutant and wild-type molecules to bind and present TSST-1 to T cells and to present an antigenic peptide to antigen-specific T cell clones were analyzed. The data indicate that the substitutions at DKot residues 36 and 39 caused a significant reduction in the ability of the DR7 molecule to bind and present TSST-1, whereas substitutions at positions 24 and 65 abrogated recognition by the tetanus toxin-specific T cell clones.
Materials and Methods
eDNA Clones and Site-directed Mutagenesis. cDNA clones encoding full-length HLA-DR(cx) and DR(~l"0701) chains (12) in the pcD expression vector (13) were used in this study. Site-directed mutagenesis of the DRc~ chain was performed by the PCR overlap extension method (14) , using Taq DNA polymerase and a DNA Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT). The four 17-mer primers used in the amplifications were located on the pcD vector near the 5' end of the cDNA, around the desired mutation positions, and codons corresponding to amino acids 145-150 of the DRc~ chain, respectively. After the two-step PCK amplifications, the PCK-amplified fragment containing the mutation was digested with the restriction enzymes SacI (New England Biolabs, Beverly, MA) and Csp45I (Promega Biotec, Madison, WI). The 476-bp SacI-Csp45I fragment from the 5'-untranslated region to the codon corresponding to amino acid 123 of the DRc~ chain was ligated into the SacI-Csp45I-digested pcD vector containing the remainder of the DRA cDNA. Dideoxy sequencing with Sequenase T7 DNA polymerase (United States Biochemical Corp., Cleveland, OH) of the region between the Sad and Csp45I sites was used to confirm the presence of the desired mutation and absence of misincorporations.
Transfection. The mutant or wild-type DRA cDNA was cotransfected with the wild-type DRBI*0701 cDNA into the DAP.3 subdone of class II-negative routine L fibroblasts as described (12) . and FITC antibody without prior addition of TSST-1. The results are presented as the relative fluorescence of the cells stained with TSST-1 normalized to the fluorescence of the same cells stained with an anti-DR mAb, as described in the legend to Fig. 1 T Cell Clones and Proliferation Assay. T cell clones specific for TSST-1 were derived from PBL stimulated in vitro with 50 ng/ml of TSST-1. After 7 d the cells were cloned by limiting dilution as described (17) . T cell clones specific for the tetanus toxin (tt) pep- Table 1 . * The ability of each mutant to bind TSST-1 is categorized as follows: -, TSST-1 concentration required to induce 50% of wild-type binding is >5 #g/ml; +, TSST-1 concentration required to induce 50% of wild-type binding is between 5 and 1/~g/ml; + +, TSST-1 concentration required to induce 50% of wild-type binding is <1/zg/ml. TSST-1 binding to each mutant was analyzed at least five times. * The ability of each mutant to present TSST-1 to at least three different TSST-l-specific T cell clones is categorized as follows: -, TSST-1 concentration required to induce 50% of proliferative response to the wild type is >10 ng/ml; +, TSST-1 concentration required to induce 50% of proliferative response to the wild-type is between 0.1 and 10 ng/ml; + +, TSST-1 concentration required to induce 50% of proliferative response to the wild-type is <0.1 ng/ml. S The ability of each mutant to present tt 830-843 to three different peptide-specific T cell clones is categorized as follows: -, peptide concentration required to induce 50% of proliferative response to the wild type is >10/zg/ml; +, peptide concentration required to induce 50% of proliferative response to the wild type is between 0.1 and 10/~g/ml; + +, peptide concentration required to induce 50% of proliferative response to the wild type is <0.1/~g/ml. II In this case, the expression of DR was always low (for analysis of DR expression see Materials and Methods). tide 830-843 were isolated and characterized as described (17) . Three independent DR7-restricted, tt830-843-specific T cell dones (SP6.6, SP2.2, and SP3.12) and four TSST-l-specific T cell clones (ALp2.12. 
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Production of DRcr Mutants.
To analyze the contribution of individual amino acids in the ol chain of HLA-DR molecules in the interaction with TSST-1, 21 mutated DR7 molecules containing single amino acid substitutions in the oe chain were constructed by site-directed mutagenesis and transfected in mouse L ceUs. Since human HLA-DP and murine I-E molecules do not bind TSST-1, or bind it poorly, and I-E molecules do not present TSST-1 (5-7, 9), most of the mutations involve replacement of the DRol residue with the corresponding residue from the c~ chain of HLA-DP or I-E molecules, as shown in Table 1 . The predicted location of the substituted positions in the class II molecule, according to the model of Brown et al. (18) , are shown in Fig. 1 . The residues at positions 7, 9, 11, 22, 24, and 31 are predicted to be located on the floor of the peptide binding groove, with their side chains pointing up toward the peptide binding groove. The residues at positions 15, 18, and 19 are predicted to be located on the outer loop that connects the first and second /~ strands. The residues at positions 36, 37, 39, and 42 are predicted to be located on an outer loop that connects the third and fourth 3 strands. The residues at positions 47, 49, 50, 55, 65, 66, and 72 are predicted to be located in the oe helix with their side chains pointing in toward the peptide binding groove. The level of D R expression by the various transfectants was tested before each experiment by indirect immunofluorescence utilizing three different anti-DR mAbs and flow cytometric analysis. All the transfectants utilized in this study showed good levels of D R expression with at least one of the mAbs utilized, except the 66 D-V mutant that had a low level of expression. for their abilities to bind TSST-1. The data from one representative experiment are shown in Fig. 2 a and data from multiple experiments are summarized in Table 1 . We found a marked difference in the level of binding of TSST-1 (corrected for DR expression) between the wild-type and the mutants at residues 36, 39, and 66 (D-V). The level of class II expression by the transfectant expressing the 66 D-V mutant was consistently lower than the other transfectants; therefore, the apparent absence of binding to the 66 D-V mutant must be interpreted cautiously. There was no significant difference in the level of binding of TSST-1 between the wild-type and the other mutants. The residues at positions 36 and 39 were replaced with the residues found at the same positions of the murine I-Ec~ chain, which binds TSST-1 poorly or not at all (6, 7, 9) . We also calculated the estimated affinity of TSST-1 for the wild-type molecule and for the various mutant molecules using the double reciprocal plot method previously described for the calculation of the affinity ofhaptenantibody interaction (19) . The estimated affinity is expressed as K0 and it is equal to the reciprocal of the free TSST-1 concentration at which half the concentration of MHC binding sites are bound to TSST-1. We found that the K0 of TSST-1 binding for the wild-type is 1.8 • 10 -7 M, while the Ko for the point mutants at residues 36 and 39 are 10-fold higher, being 1.6 and 1.1 x 10 -6 M, respectively. This indicates that the methionine at position 36 and the lysine at position 39 are critical for TSST-1 binding.
Binding of TSST1 to HLA-DR7 Molecules and Stimulation of V~2 + T Cell Clones Are Affected by Mutations at Two
In a previous study, it was found that T cell proliferation is a more sensitive assay for TSST-l-class II interaction than the binding assay. TSST-1 binding to HLA-DP was not detected, although DP efficiently presented TSST-1 to T cells (7, 20) . Therefore, the ability of the DRcr mutants to present TSST-1 to three specific T cells was tested. The dose-response curves of one representative T cell clone with transfectants expressing wild-type or mutant DRcr chains (Fig. 2 b) show that, consistent with the results obtained in the direct binding assay, mutations at positions 36 and 39 significantly reduce the recognition of TSST-1 by the T cell. In contrast, the 66 D-V mutant presented TSST-1 to the T cell clones, suggesting that the failure to detect TSST-1 binding to this mutant was due to low class II expression. All the other mutants presented TSST-1 to the T cell clones, indicating that the MHC-TSST-1 complex is not altered by the introduction of the mutation. Interestingly, the nonconservative 37 K-S substitution had no effect on TSST-1 binding or presentation, in contrast with the results with the position 36 and 39 mutations. These results are consistent with the predictions of the class II model and the view that superantigens interact with the outer surfaces of class II molecules: although residues 36, 37, and 39 are predicted to be located on an outer loop, only the side chain of residue 37 is predicted to point in toward the peptide binding groove.
Presentation of tt 830-843 by Transfectants Expressing DRol
Mutants. To assess whether any of the single substitutions in the DRo~ chain causes gross alterations of the conformation of the DR molecules, we tested the ability of these mutants to present peptide antigen. Three independent DR7-restricted T cell clones were tested for their abilities to recognize peptide tt 830-843 presented by transfected cells. The proliferative response of one representative clone is shown in Fig. 3 . We found that the substitutions of a methionine to an isoleucine at residue 36 and of a lysine to a serine at residue 39 do not affect the ability of these mutants to present peptide antigen. This indicates that the mutants bind the peptide and that the peptide-MHC complex is recognized by the specific TCR. Our results are consistent with the view that the binding site for toxin superantigens is different from the conventional antigen binding site (5, 10, 11) . We also found that substitutions at positions 24 and 65 abrogated recognition by the tt-specific T cells, although they have no effect on TSST-1 binding and presentation. The substitutions at positions 22 and 66 D-V reduced the ability of the DR7 molecule to present peptide. The findings that only 2 of the 21 DRcr mutations abrogated the ability of the DR7 molecule to present the tt peptide to the three T cell clones are in marked contrast to the results of our previous analysis of DRB mutations on tt presentation in which multiple mutations abrogated T cell proliferation (21 Concluding Remarks. The present study demonstrates that residues 36 and 39 on the DRo~ chain are critical for TSST-1 binding and presentation to specific T cells. Recently it has been demonstrated that the second hypervariable region of the mouse Ac~ chain (olHV2) is the single most important c~ chain polymorphic region that contributes to the TSST-1 binding site (22) . Indeed, residues 36 and 39 are predicted to be located in the region analogous to o~HV2 on the outer loop of the c~ chain that connects the third and the fourth strands. Our data suggest the existence of a high a~nity binding site on DILc~ chain for TSST-1, since alteration of two closely located residues, 36 and 39, can significantly reduce TSST-1 binding and presentation. However, at high TSST-1 concentrations a certain level of binding and presentation by these mutants is observed (Fig. 2) , indicating that a low ai~nity binding site might still be available. Therefore, the substitution at one residue may decrease the af~nity of TSST-1 binding to MHC, rather than abolishing the binding.
Previous studies indicate the existence of different binding sites, some of which may be overlapping, for staphylococcal toxins on class II molecules (23, 24) . Two SEA binding sites have been postulated, but previous studies indicate a single TSST-1 binding site. DRB residue 81, which is predicted to be located in a region of interchain interaction with the oe chain, has been shown to be involved in the SEA and SEE binding site (11, 25) . We found that a histidine to alanine substitution at position 81 in the DIL(~l*0701) chain does not prevent binding and presentation of TSST-1 (data not shown). However, analysis of TSST-1 binding to additional mutants will be required to further investigate the possible contributions of DRB chain residues to TSST-1 binding (22) .
